Incyte Corporation (INCY): Price and Financial Metrics


Incyte Corporation (INCY): $69.00

-0.78 (-1.12%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add INCY to Watchlist
Sign Up

Industry: Biotech


Ranked

of 505

in industry

INCY POWR Grades


  • INCY scores best on the Quality dimension, with a Quality rank ahead of 96.04% of US stocks.
  • The strongest trend for INCY is in Momentum, which has been heading down over the past 48 weeks.
  • INCY's current lowest rank is in the Momentum metric (where it is better than 5.12% of US stocks).

INCY Stock Summary

  • Of note is the ratio of Incyte Corp's sales and general administrative expense to its total operating expenses; merely 14.12% of US stocks have a lower such ratio.
  • The ratio of debt to operating expenses for Incyte Corp is higher than it is for about just 6.15% of US stocks.
  • Over the past twelve months, INCY has reported earnings growth of -438.29%, putting it ahead of merely 4.95% of US stocks in our set.
  • Stocks that are quantitatively similar to INCY, based on their financial statements, market capitalization, and price volatility, are SIMO, MCRB, SRPT, EIGR, and CHRS.
  • Visit INCY's SEC page to see the company's official filings. To visit the company's web site, go to www.incyte.com.

INCY Valuation Summary

  • INCY's price/earnings ratio is 50; this is 36.99% higher than that of the median Healthcare stock.
  • Over the past 243 months, INCY's price/earnings ratio has gone up 80.3.
  • Over the past 243 months, INCY's EV/EBIT ratio has gone up 86.9.

Below are key valuation metrics over time for INCY.

Stock Date P/S P/B P/E EV/EBIT
INCY 2021-08-31 6.2 5.8 50.0 37.1
INCY 2021-08-30 6.2 5.7 49.7 36.9
INCY 2021-08-27 6.1 5.7 49.5 36.7
INCY 2021-08-26 6.1 5.7 49.2 36.4
INCY 2021-08-25 6.1 5.7 49.6 36.7
INCY 2021-08-24 6.1 5.7 49.4 36.6

INCY Growth Metrics

  • Its 5 year price growth rate is now at -17.64%.
  • The 4 year net cashflow from operations growth rate now stands at -168.07%.
  • The 5 year revenue growth rate now stands at 251.73%.
Over the past 33 months, INCY's revenue has gone up $922,942,000.

The table below shows INCY's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 2,720.579 668.475 337.638
2021-03-31 2,702.913 764.913 478.48
2020-12-31 2,666.702 -124.599 -295.697
2020-09-30 2,456.582 -100.302 -334.542
2020-06-30 2,387.52 -12.002 -191.068
2020-03-31 2,229.409 -128.424 -376.048

INCY's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • INCY has a Quality Grade of A, ranking ahead of 96.04% of graded US stocks.
  • INCY's asset turnover comes in at 0.754 -- ranking 190th of 556 Business Services stocks.
  • LQDT, PEGA, and AER are the stocks whose asset turnover ratios are most correlated with INCY.

The table below shows INCY's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.754 0.949 0.381
2021-03-31 0.787 0.951 0.523
2020-12-31 0.831 0.951 -0.231
2020-09-30 0.774 0.948 -0.298
2020-06-30 0.758 0.949 -0.138
2020-03-31 0.723 0.947 -0.388

INCY Price Target

For more insight on analysts targets of INCY, see our INCY price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $102.47 Average Broker Recommendation 1.58 (Moderate Buy)

INCY Stock Price Chart Interactive Chart >

Price chart for INCY

INCY Price/Volume Stats

Current price $69.00 52-week high $101.47
Prev. close $69.78 52-week low $68.62
Day low $68.62 Volume 1,407,300
Day high $70.14 Avg. volume 1,271,874
50-day MA $75.40 Dividend yield N/A
200-day MA $82.12 Market Cap 15.24B

Incyte Corporation (INCY) Company Bio


Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics in oncology in the United States and internationally. The company was founded in 1991 and is based in Wilmington, Delaware.


INCY Latest News Stream


Event/Time News Detail
Loading, please wait...

INCY Latest Social Stream


Loading social stream, please wait...

View Full INCY Social Stream

Latest INCY News From Around the Web

Below are the latest news stories about Incyte Corp that investors may wish to consider to help them evaluate INCY as an investment opportunity.

Incyte, Knight Therapeutics Ink Distribution Pact For Two Cancer Drugs In Latin America

Knight Therapeutics Inc has acquired exclusive rights from Incyte Corporation (NASDAQ: INCY) to distribute tafasitamab and pemigatinib (Pemazyre) in Latin America. Related: Incyte's Pemazyre Wins Conditional Approval For Bile Duct Cancer In Canada. Under the agreement terms, Incyte will be responsible for developing, manufacturing, and supplying tafasitamab and pemigatinib. Knight will be responsible for seeking the necessary regulatory approvals distributing both medicines in Latin America. Taf

Yahoo | September 23, 2021

Incyte (INCY) Jakafi Wins FDA Approval for Chronic GVHD

Incyte's (INCY) going gets good with another FDA approval - Jakafi for the treatment of chronic GVHD. However, the stock witnesses a decline despite the recent approvals.

Yahoo | September 23, 2021

BriaCell's Survival Story Could Mean a Better Chance of Survival for Women Suffering from Breast Cancer

Photo by Artem Podrez from Pexels Too many companies and small businesses to count were buried under the avalanche of a global pandemic in the past 18 months. And as horrible as it was to lose your favorite restaurant or dry cleaner, imagine the impact of losing a company that had devoted itself to enhancing the lives of women with breast cancer. Fortunately, due to some investment creativity and all-out perseverance, BriaCell Therapeutics Corp. (Nasdaq: BCTX) (Nasdaq: BCTXW) (TSX-V: BCT) has su

Yahoo | September 23, 2021

Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Incyte for Tafasitamab and Pemigatinib in Latin America

MONTREAL, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, today announced that it has entered into a definitive agreement with Incyte Biosciences International Sàrl, the Swiss-based affiliate of Incyte (NASDAQ:INCY), for the exclusive rights to distribute tafasitamab (sold as Monjuvi® in the United States and Minjuvi® in Europe) and pemigatinib (Pemazyre®) in Latin America. Under the terms of the agreeme

Yahoo | September 23, 2021

Back To Back FDA Approval For Incyte - This Time For Jakafi In GVHD

The FDA has approved Incyte Corporation''s (NASDAQ: INCY ) approved Jakafi (ruxolitinib) for chronic graft-versus-host disease (GVHD). The approval comes for adult and pediatric patients 12 years and older with GVHD after the failure of one or two lines of systemic therapy. The approval was based on Phase 3 REACH3 study of Jakafi Full story available on Benzinga.com

Benzinga | September 22, 2021

Read More 'INCY' Stories Here

INCY Price Returns

1-mo -8.83%
3-mo -19.40%
6-mo -14.00%
1-year -20.28%
3-year -0.06%
5-year -22.53%
YTD -20.67%
2020 -0.39%
2019 37.32%
2018 -32.86%
2017 -5.55%
2016 -7.54%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9158 seconds.